Key Highlights

  • 1Q FY27 revenue was $95.7m, down 2%, with gross margin of 63%.
  • Underlying EBITDA was $5.3m, compared with $11.0m a year earlier.
  • BIJUVA prescriptions rose 25%, IMVEXXY 13% and NEXTSTELLIS demand cycles 27%.
  • Multiple legal settlements were executed during the quarter.

Mayne Pharma Group Limited (ASX:MYX) announced unaudited first quarter FY27 results on 26 October 2026 for the three months ended 30 September 2026, showing higher Women's Health demand offset by lower Dermatology sales and a decline in earnings.

Group financials

Revenue was $95.7 million, down $2.0 million or 2% on the first quarter of FY26. Gross profit was $60.3 million, down 8%, direct contribution was $23.3 million, down 23%, and underlying EBITDA was $5.3 million, down 52% from $11.0 million. Gross margin was 63%. The company said growth in Women's Health was offset by a decline in Dermatology branded sales from anticipated competitive erosion.

Women's Health and DistributeRx

Total prescriptions for BIJUVA rose 25% versus the prior corresponding period, IMVEXXY 13% and NEXTSTELLIS demand cycles 27%. DistributeRx delivered 84,000 total prescriptions, up 120%, from about 6,000 unique prescribers, and its automated Adelaide Apothecary facility in Lexington, Kentucky is on track to start operations in early 2027. An exclusive five-year licence with Italfarmaco for BLISSEL in Australia extends the menopause portfolio.

Legal matters

Paragraph IV patent litigation settlements for IMVEXXY were reached with Sun Pharma and Teva Pharmaceuticals USA, announced on 30 September and 16 October. A legacy generic drug pricing civil action was resolved with State attorneys general for a one-time payment of US$0.65 million with no admission of liability, subject to court approval. The Court of Appeal upheld the Supreme Court judgment in Mayne Pharma's favour in the Cosette proceedings, with costs, and the damages claim continues.

Why This Could Matter

The quarter shows prescription growth in the Women's Health products alongside lower overall revenue and earnings, because of reduced Dermatology sales. The legal outcomes address patent, pricing and contractual matters that had been outstanding, with some subject to court approval or continuing proceedings.

Wrapping Up

Mayne Pharma (ASX:MYX) reported $95.7 million of revenue and $5.3 million of underlying EBITDA for 1Q FY27, with growing Women's Health demand and several legal settlements.